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he bioactive phospholipids, lysophosphatidic acid
(LPA) and phosphatidic acid (PA), regulate pivotal
processes related to the pathogenesis of cancer.
Here, we report characterization of a novel lipid kinase,
designated acylglycerol kinase (AGK), that phosphory-
lates monoacylglycerol and diacylglycerol to form LPA
and PA, respectively. Confocal microscopy and subcellu-
lar fractionation suggest that AGK is localized to the mito-
chondria. AGK expression was up-regulated in prostate
cancers compared with normal prostate tissues from the
same patient. Expression of AGK in PC-3 prostate cancer
T
 
cells markedly increased formation and secretion of LPA.
This increase resulted in concomitant transactivation of the
EGF receptor and sustained activation of extracellular sig-
nal related kinase (ERK) 1/2, culminating in enhanced
cell proliferation. AGK expression also increased migra-
tory responses. Conversely, down-regulating expression
of endogenous AGK inhibited EGF- but not LPA-induced
ERK1/2 activation and progression through the S phase
of the cell cycle. Hence, AGK can amplify EGF signaling
pathways and may play an important role in the patho-
physiology of prostate cancer.
 
Introduction
 
Originally known for its pedestrian role as an intermediate in
intracellular lipid metabolism, lysophosphatidic acid (LPA) is
now recognized as a potent lipid mediator that evokes growth
factor–like responses and regulates an array of cellular pro-
cesses related to pathogenesis of cancer (Mills and Moolenaar,
2003). Progress in understanding LPA actions has accelerated
with the discovery that it is a ligand of several G protein–coupled
receptors (GPCRs), termed LPA
 
1
 
, LPA
 
2
 
, and LPA
 
3
 
 (Mills and
Moolenaar, 2003). Intriguingly, expression of LPA receptors
correlates with more advanced prostate cancer cell lines (Gibbs
et al., 2000). In addition to actions through conventional GPCR
signaling pathways, LPA receptors can indirectly regulate cell
functions by transactivating the EGF tyrosine kinase receptor
(Prenzel et al., 1999). This cross-communication between dif-
ferent signaling systems is not only important for the growth-
promoting activity of LPA (Prenzel et al., 1999) but it may also
be a clue to its pathophysiological role in prostate cancer (Pren-
zel et al., 1999). The recent discovery that LPA can be gener-
ated in the extracellular milieu from lysophosphatidylcholine
by the ectoenzyme autotaxin, known to be involved in tumor
invasion, neovascularization, and metastasis (Umezu-Goto et
al., 2002), further supports the notion that LPA is an important
regulator of tumor progression (Mills and Moolenaar, 2003).
A potential pathway for synthesis of LPA is the phosphor-
ylation of monoacylglycerol by a specific lipid kinase (Pieringer
and Hokin, 1962), an enzyme that has remained an enigma for
more than 40 yr. We have now cloned and characterized a novel
acylglycerol kinase (AGK) that phosphorylates both monoac-
ylglycerol to form LPA and diacylglycerol to produce phos-
phatidic acid (PA), another potent lipid second messenger that
mediates mitogenic activation of mTOR (mammalian target of
rapamycin) signaling (Fang et al., 2001). LPA produced by AGK
in turn activates the EGF receptor, amplifying mitogenic and
survival signals and regulating EGF-directed motility. Our re-
sults suggest that AGK, which is highly expressed in prostate
cancers, might be important for the initiation and progression of
prostate cancer, processes in which LPA plays prominent roles
(Prenzel et al., 1999; Kue and Daaka, 2000; Kue et al., 2002; Xie
et al., 2002; Mills and Moolenaar, 2003).
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Results
 
A new lipid kinase catalyzes the 
phosphorylation of acylglycerols to 
generate LPA and PA
 
While searching for additional isoforms of sphingosine kinase
(SphK), the enzyme that catalyzes the formation of sphingo-
sine-1-phosphate (S1P), another serum-borne lysophospholipid
structurally similar to LPA, we cloned a related gene that en-
codes a 422–amino acid protein (Fig. S1, available at http://
www.jcb.org/cgi/content/full/jcb.200407123/DC1). Although
this new kinase was cloned based on its homology to SphKs, it
only displayed barely detectable phosphorylating activity with
sphingosine as substrate when compared with cells transfected
with SphK1 or SphK2 (Fig. 1 A). Moreover, there were no de-
tectable changes in the levels of the sphingolipid metabolites,
ceramide, sphingosine, or S1P, in cells overexpressing this
lipid kinase. Furthermore, when AGK transfectants were la-
beled with [
 
3
 
H]sphingosine, there were no significant increases
detected in the formation of [
 
3
 
H]S1P compared with vector-
transfected cells (unpublished data).
We examined in vitro kinase activity with an array of lipid
substrates, including different ceramide species and glycerolip-
ids, such as 1,2-dioleoyl-
 
sn
 
-glycerol (DAG), glycerol-3-phos-
phate, anandamide, phosphatidylinositol, phosphatidylglycerol,
cardiolipin, and the monoacylglycerol 1-oleoyl-2-
 
sn
 
-glycerol
(MOG). Significant phosphorylated products were only detected
with monoacylglycerols and diacylglycerols as substrates, but
not with any other lipid tested, including ceramide and sphingo-
sine (Fig. 1 B); thus, we have designated this lipid kinase as an
AGK. Although AGK contains a DAG kinase (DAGK) catalytic
domain (Fig. S1), it did not significantly phosphorylate DAG
when activity was measured in the presence of the detergent
octyl-
 
 
 
-glucopyranoside (Fig. 1 B), as usually used for DAGK
activity measurements (Bunting et al., 1996), suggesting that
AGK is distinct from other known DAGKs.
Previously, a partially purified bovine brain monoacylglyc-
erol kinase (MAGK) was reported to prefer substrates containing
unsaturated fatty acid esters (Shim et al., 1989; Simpson et al.,
1991). Interestingly, AGK has higher activity with substrates
containing a C18 fatty acid with one double bond, as monoacyl-
glycerol with an oleoyl (18:1) substitution in the 
 
sn1
 
 position
was phosphorylated to a greater extent than 1-palmitoyl-2-
 
sn
 
-
glycerol (16:0), which was a better substrate than 1-stearoyl-2-
 
sn
 
-glycerol (18:0) (Fig. 1 B). Moreover, 1-
 
sn
 
-2-arachidonoyl-
glycerol, an endogenous cannabinoid receptor ligand (Sugiura et
al., 2000), was also a reasonably good substrate (Fig. 1 B). Like
the crude bovine brain MAGK activity (Shim et al., 1989), AGK
required magnesium for maximal activity, whereas other diva-
lent cations, including Ca
 
2
 
 
 
 and Zn
 
2
 
 
 
, inhibited phosphorylation
of MOG. Similar to brain MAGK, AGK also had higher activity
in the presence of 0.03% deoxycholate, although enzymatic ac-
tivity was completely abolished by most other detergents, in-
cluding Triton X-100, Triton X-114, CHAPS, and 
 
 
 
-octylglu-
copyranoside (Fig. 1 B and not depicted).
While this manuscript was in revision, Waggoner et al.
(2004) showed that AGK expressed in bacteria phosphorylates
DAG as well as MOG and ceramide, but not sphingosine,
whereas in lysates of AGK-overexpressing cells, ceramide was
not phosphorylated (Fig. 1 B), nor did we detect any phosphor-
ylation of ceramide or sphingosine in vivo.
 
Subcellular localization of AGK
 
Confocal immunofluorescence microscopy revealed that AGK
was distributed in a punctate, reticular pattern in NIH 3T3
cells (Fig. 2 A), which is reminiscent of a mitochondrial local-
ization. There was no significant colocalization with the ER
marker calnexin (Fig. 2 A). On the other hand, AGK expression
clearly colocalized with mitochondria stained with MitoTracker
red (Fig. 2 A). Similar mitochondrial localization of AGK was
also observed in HEK 293 and PC-3 cells (Fig. S2 A, available
at http://www.jcb.org/cgi/content/full/jcb.200407123/DC1),
indicating that the subcellular distribution was not cell type
specific. In agreement, although AGK does not contain a ca-
nonical mitochondrial localization signal, the MitoProt II web-
site predicts an 80% probability of mitochondrial localization,
Figure 1. Lipid kinase activity of recombinant
AGK.  (A) NIH 3T3 cells were transiently
transfected with vector, hSphK1, hSphK2, or
hAGK. After 24 h, cells were lysed and
sphingosine-phosphorylating activity in cell
lysates was measured with 50  M D-erythro-
sphingosine (Sph) substrate added as a BSA
complex as described previously (Liu et al.,
2000). (B) Lipid-phosphorylating activity was
determined in cell lysates from NIH 3T3 cells
transiently transfected with vector (open bars)
or hAGK (closed bars). The following lipids
were tested: Sph, C6-cer; 1-oleoyl-2-sn-glyc-
erol (18:1), MOG; 2-arachidonoyl-glycerol
(20:4), 2-AG; 1-palmitoyl-2-sn-glycerol (16:
0), MPG; 1-stearoyl-2-sn-glycerol (18:0),
MSG; or diacylglycerol (1,2-dioleoyl-sn-glyc-
erol), DAG. Where indicated, octyl- -glu-
copyranoside detergent was added to a final
concentration of 1.5%. The data are ex-
pressed as picomoles of phosphorylated
product formed per minute per milligram   SD. Similar results were obtained in four additional experiments. *, P   0.05 by t test. (C) TLC separation
of products formed with MOG as substrate visualized with a phosphoimager. 
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and the program TMpred predicted one transmembrane region
from amino acid 11 to 30.
To further substantiate the localization of AGK, protein
expression and enzymatic activity were examined in subcel-
lular fractions prepared by differential centrifugation. V5-
Epitope–tagged AGK with the predicted MW of 46.4 kD was
highly enriched in the P2 mitochondria fraction (Fig. 2 B).
Much less AGK was present in the P3 fraction containing intra-
cellular membranes of the ER and Golgi or in the P4 plasma
membrane fraction. In concordance with the protein expression
pattern, the highest AGK-specific activity was in P2 (Fig. 2 C).
 
AGK regulates LPA and PA in vivo
 
To definitively demonstrate that AGK has intrinsic kinase activ-
ity rather than affecting the activity of some endogenous lipid
kinase, phosphorylation of acylglycerol substrates after specific
pull-down of epitope-tagged AGK expressed in HEK 293 cells
with V5 antibody was determined. Although the V5 antibody
inhibits AGK, phosphorylation of MOG was sixfold greater in
immunoprecipitates from V5-AGK transfectants than vector
transfectants (Fig. 2 D) and there was no significant phosphory-
lating activity with other lipid substrates (not depicted).
To identify the phosphorylated lipids produced by AGK
in vivo, vector and AGK PC-3 transfectants were incubated
with 
 
32
 
P-labeled orthophosphate and labeled phospholipids in
isolated mitochondria examined (Fig. 3 A). Expression of AGK
resulted in 80% increase of 
 
32
 
P-labeled PA without significantly
affecting labeling of the other mitochondrial phospholipids. Be-
cause it is known that LPA synthesized in mitochondria can
readily exit this organelle (Chakraborty et al., 1999) or be rap-
idly metabolized to PA, changes in total cellular phospholipids
were also examined (Fig. 3, B–D). There were no obvious dif-
ferences in labeling of the major known cellular phospholipids
in AGK-expressing cells compared with the vector cells. How-
ever, two-dimensional HPTLC analysis revealed that a labeled
phospholipid that comigrated with authentic LPA (Fig. 3, B and
C), although barely detectable in vector cells, was increased
threefold in AGK-expressing cells. Moreover, this phospholipid
was eliminated by treatment with phospholipase B, which hy-
drolyzes the ester bonds of lysophospholipids, confirming its
identity as LPA. Labeled PA was also increased in these trans-
fectants (Fig. 3 D), albeit much less than LPA. Of note, in these
cells, AGK mRNA levels relative to 18S RNA were increased
by almost twofold over endogenous expression from 1.2 
 
 
 
 0.1
to 2.3 
 
 
 
 0.2, as determined by quantitative PCR.
It has previously been shown that cancer cells secrete
LPA (Mills and Moolenaar, 2003). Small amounts of labeled
lysophospholipids, including LPA, were secreted by vector
transfected PC-3 cells. However, secretion of 
 
32
 
P-labeled LPA
was significantly increased threefold by overexpression of
AGK (Fig. 3, F and G), indicating that AGK increases both in-
tracellular and extracellular levels of LPA. It should be noted
that AGK was not detectable in the medium by immunoblotting
nor did its expression cause apoptosis of cells, suggesting that
appearance of LPA in the media is not a result of cell death.
All members of the DAGK and SphK superfamily have a
conserved GDG sequence in the glycine-rich loop of the putative
ATP binding region and a single point mutation of the second
conserved glycine residue to aspartate has been used to prepare
catalytically inactive DAGK (Topham and Prescott, 1999) and
SphK (Pitson et al., 2002). Similarly, site-directed mutagenesis of
the equivalent residue in AGK (G126E) resulted in a complete
loss of phosphorylating activity (Fig. S2 B), and its expression had
no discernible effects on 
 
32
 
P-labeled LPA, PA, or other phospho-
lipids (Fig. S2 C). However, like wild-type AGK, this catalytically
inactive mutant was localized to the mitochondria (Fig. S2 A)
Figure 2. Subcellular localization of AGK.
(A) NIH 3T3 fibroblasts were transiently trans-
fected with V5-tagged AGK and mitochondria
stained with MitoTracker red. The ER was visu-
alized with anti-calnexin antibody followed by
FITC-conjugated anti-rabbit as the secondary
antibody. AGK was stained with monoclonal
anti-V5 antibody followed by secondary FITC-
conjugated or Texas red–conjugated anti–
mouse antibody. Cells were visualized by
dual wavelength confocal microscopy. Super-
imposed merged pictures are shown in the
bottom panels, with yellow indicating colocal-
ization. (B and C) Activity and expression of
AGK in subcellular fractions. Lysates from HEK
293 cells transfected with vector or V5-AGK
and P2 (mitochondria), P3 (ER and Golgi), P4
(plasma membrane), and cytosol fractions iso-
lated. The P1 fraction containing nuclei and
unbroken cells was not examined. 25  g of
proteins were resolved by SDS-PAGE and im-
munoblotted with anti-V5 antibody or with an-
tibodies to the specific organelle markers
anti–cytochrome c oxidase, anti-phosphodisul-
fide isomerase (PDI), and anti– v-integrin.
AGK activity was also determined in each subcellular fraction with MOG as substrate. Results are means   SD of triplicate determinations. Similar results
were obtained in two additional experiments. *, P   0.05 by t test. (D) 400- g aliquots of lysates from HEK 293 cells transiently transfected with vector
(open bars) or V5-AGK (closed bars) were immunoprecipitated with anti-V5 antibody as described in Materials and methods, and AGK activity was deter-
mined in the immunoprecipitates. Data are expressed as picomoles of LPA formed in 30 min and are means   SD of duplicate determinations. 
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AGK is highly expressed in prostate 
cancer
 
As LPA has been most prominently associated with growth-
promoting effects and probably contributes to cancer (Mills
and Moolenaar, 2003), it was of interest to examine the ex-
pression of AGK in normal tissues and cancers. By Northern
analysis, a 2.6-kb AGK mRNA was widely expressed (Fig. 4
A), most abundantly in heart, kidney, muscle, and brain. Im-
portantly, using a matched human tumor/normal tissue ex-
pression array, we found that AGK expression was signifi-
cantly up-regulated in prostate cancers compared with the
normal prostate tissues from the same patient (Fig. 4 B).
However, not all tumor tissues show an increase in AGK ex-
pression. In uterine, cervical, and stomach cancers, there also
appeared to be higher expression of AGK compared with the
normal tissues, whereas AGK expression seems to be reduced
in colon cancer. AGK was also expressed in many types of
human cancer cell lines (Fig. 4 B), including prostate cancer
cells, such as androgen-responsive LNCaP cells, which are
more similar to early stage carcinoma, and androgen-insensi-
tive TSU-Pr1 and PC-3 cells, a model for more advanced
prostate carcinoma.
Figure 3. Effect of AGK on phospholipids.
(A) PC-3 cells stably transfected with vector or
AGK were labeled with 
32P-orthophosphate
for 2 h. Phospholipids were then extracted
from mitochondria isolated by differential cen-
trifugation. After separation of equal amounts
of 
32P-labeled phospholipids by one-dimen-
sional TLC, radioactive spots were visualized
with a phosphoimager and the indicated lip-
ids were identified based on comigration with
authentic standards. The ratio of 
32P-PA to
32P-PC in vector and AGK transfectants was
0.38   0.02 and 0.68   0.03, respectively.
(B–G). LPA production and secretion induced
by expression of AGK. PC-3 cells stably trans-
fected with vector or AGK were prelabeled
with 
32P-orthophosphate for 2 h, washed, and
incubated for 2 h in chemically defined me-
dium. Lipids were extracted from cells (B–D)
and media (E–G). Equal amounts of 
32P-phos-
pholipids were separated by two-dimensional
HPTLC, first in chloroform/methanol/formic acid/water (60:30:7:3, vol/vol), followed by chloroform/methanol/ammonium hydroxide/water (50:40:8:2,
vol/vol). Radioactive spots were visualized with a phosphoimager, and the indicated lipids were identified based on comigration with authentic standards.
(D and G) 
32P incorporation into the indicated phospholipids (LPA, PA, PC, and unidentified phospholipid [X]) was quantified by phosphoimager. Similar
results were obtained in two additional experiments.
Figure 4. Expression of hAGK. (A) Northern
blot analysis of hAGK expression in human tis-
sues. Random labeled probe was hybridized
to poly(A)
  RNA blots from the indicated hu-
man tissues.  -Actin expression was used to
confirm equal loading. (B) Matched tumor/
normal array analysis of hAGK expression.
An array containing cDNA samples from mul-
tiple tissues and tumor types as well as nine
cancer cell lines was probed with 
32P-labeled
AGK probe. Each pair of tumor and normal
samples came from the same patient. Human
cancer cell lines: (1) HeLa; (2) Burkitt’s lym-
phoma, Daudi; (3) chronic myelogenous leu-
kemia; (4) promyelocytic leukemia HL-60; (5)
melanoma; (6) lung carcinoma; (7) lympho-
blastic leukemia, MOLT-4; (8) colorectal ade-
nocarcinoma, SW480; (9) Burkitt’s lymphoma,
Raji. There was no specific hybridization to
the control nucleic acids, which included ubiq-
uitin cDNA, yeast total RNA, yeast tRNA,
Escherichia coli DNA, poly(A), human Cot-1
DNA, and human genomic DNA. (C–E) AGK
stimulates proliferation. PC-3 cells stably trans-
fected with vector (open symbols) or AGK
(closed symbols) were cultured in serum-free medium supplemented with 0.5% serum (C), 10  M LPA (D), or 10  M MOG (E), and cell numbers deter-
mined at the indicated days. Data are expressed as fold increase relative to day 0 and are means   SD. Similar results were obtained in two additional
experiments. Asterisks denote significant differences (P   0.05, t test). (F) AGK does not enhance proliferation of RH7777 cells. RH7777 cells were
cotransfected with vector (open bars) or AGK (closed bars) together with GFP at a ratio of 4:1. After 24 h, cells were cultured in serum-free medium or in
the presence of 0.5% serum. BrdU was added 16 h later for an additional 3 h. Double immunofluorescence was used to visualize transfected cells and
BrdU incorporation into nascent DNA. The proportion of cells incorporating BrdU among total GFP transfected cells was determined. Data are means   SD
of triplicate cultures from a representative experiment. At least three different fields with a minimum of 100 cells/field were scored. 
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AGK expression enhances cell growth 
through LPA receptors
 
Growth promotion is one of the most prominent effects medi-
ated by LPA (Mills and Moolenaar, 2003). Consistent with its
ability to increase LPA synthesis, transient or stable expres-
sion of AGK enhanced proliferation of diverse cell types, in-
cluding PC-3 cells (Fig. 4, C–E) and NIH 3T3 fibroblasts
(Fig. S3 A, available at http://www.jcb.org/cgi/content/full/
jcb.200407123/DC1). The growth-promoting effect of AGK
was observed even in the presence of suboptimal serum con-
centrations (Fig. 4 C and Fig. S3 A). Although AGK stimu-
lates growth, it had no cytoprotective effects on apoptosis
induced by serum deprivation or the anti-cancer drug doxoru-
bicin (Fig. S3 D). As expected, exogenous LPA increased pro-
liferation of both AGK and vector transfectants to the same ex-
tent (Fig. 4 D). Addition of MOG to cells cultured in serum-
free medium had a minimal effect on vector transfectants and
significantly stimulated proliferation of AGK-expressing PC-3
cells (Fig. 4 E). This result is probably due to rapid metabo-
lism and degradation of MOG, and thus only in AGK-express-
ing cells is sufficient LPA produced and secreted (Fig. 3, F and
G) to stimulate proliferation.
FACS analysis revealed that 83 
 
 
 
 0.4% of the vector
transfectants were in Go/G1 phase and 7.0 
 
 
 
 0.04 and 10 
 
 
 
0.4% were in S and G2/M phases, respectively. Overexpression
of AGK reduced the fraction of cells in Go/G1 to 73 
 
 
 
 0.1%
and increased the proportion in the S phase by greater than
twofold (15 
 
 
 
 0.1%), without significantly affecting the pro-
portion in the G2/M phase (12 
 
 
 
 0.1%).
Although it is well established that the mitogenic effects
of LPA in many cell types are mediated by binding to its spe-
cific GPCRs (Mills and Moolenaar, 2003), intracellular actions
have also been suggested (Hooks et al., 2001), possibly as an ag-
onist of the nuclear transcription factor peroxisome proliferator-
activated receptor-
 
 
 
 (PPAR
 
 
 
; Zhang et al., 2004). To examine
the potential involvement of intracellular actions of LPA gen-
erated by expression of AGK, its mitogenic effects were exam-
ined in rat hepatoma RH7777 cells that do not express LPA
 
1-4
 
and do not respond to LPA (Fukushima et al., 1998). However,
in contrast to PC-3 (Fig. 4, C–E) and NIH 3T3 (Fig. S3 A)
cells, RH7777 cells did not show an increase in DNA synthesis
in response to expression of AGK as measured by incorpora-
tion of BrdU into nascent DNA (Fig. 4 F). Although RH7777
cells express AGK, it is possible that they do not produce suffi-
cient amounts of LPA if MOG is limiting. However, even addi-
tion of MOG did not enhance BrdU incorporation in RH7777
cells expressing AGK (Fig. 4 F).
Similar to a previous paper (Lea et al., 2004), GW9662, a
selective antagonist of PPAR
 
 
 
, inhibited proliferation of PC-3
cells (Fig. 5 A). However, importantly, it did not abrogate the
mitogenic effect of AGK (Fig. 5 A). Consistent with previous
studies (Kue et al., 2002), we found that LPA
 
1
 
, LPA
 
2
 
, and
LPA
 
3
 
 are expressed in PC-3 cells (unpublished data). It is
known that LPA
 
1
 
 couples to pertussis toxin (PTX)–sensitive
Gi, whereas LPA
 
2
 
 and LPA
 
3
 
 couple also to Gq. In PC-3 cells,
LPA-regulated mitogenic signaling is mediated by G
 
  
 
 sub-
units derived from PTX-sensitive Gi proteins (Bookout et al.,
2003). In agreement, PTX pretreatment not only inhibited
growth of vector transfectants but it also markedly decreased
the growth-promoting effects of AGK (Fig. 5 A). However,
AGK expression enhanced cell proliferation even in the pres-
ence of PTX.
Figure 5. Regulation of cell growth and
EGFR signaling by AGK. (A) Effect of PTX and
the PPAR  antagonist GW9662 on AGK-
induced proliferation. PC-3 cells stably trans-
fected with vector (open bars) or AGK
(closed bars) were cultured in medium supple-
mented with 1% serum without or with
GW9662 (1  M or 5  M) or with PTX (100
ng/ml), and cell proliferation was determined
after 6 d with WST-1. Asterisks denote signifi-
cant differences compared with untreated con-
trols (P   0.05, t test). (B) Enforced expression
of AGK enhances EGFR tyrosine phosphoryla-
tion and stimulates ERK1/2. Serum-starved
PC-3 cells stably transfected with vector or
AGK were stimulated without or with 10% se-
rum for 10 min, lysed and immunoblotted with
anti-phosphotyrosine, anti-V5 antibody, or
phospho-specific anti-ERK1/2 antibodies.
Blots were stripped and reprobed with ERK2
antibody to demonstrate equal loading. (C)
AGK expression induces EGFR transactiva-
tion. Lysates from cells treated as in B were im-
munoprecipitated with anti-EGFR antibody
and the immunoprecipitates were analyzed by Western blotting using anti-phosphotyrosine or anti-EGFR antibody. (D and E) Blockage of EGFR signaling
suppresses ERK activation and cell growth advantage mediated by AGK. (D) Serum-starved PC-3 cells stably transfected with vector or AGK were preincu-
bated for 60 min in the absence or presence of 200 nM AG1478, and then treated with EGF for 10 min. Cell lysate proteins were analyzed by immuno-
blotting with phospho-specific ERK1/2 antibody. Blots were stripped and reprobed with ERK2 antibody to demonstrate equal loading. (E) PC-3 cells stably
transfected with vector or AGK were cultured in medium supplemented with 1 or 10% serum with or without 200 nM AG1478, and cell proliferation was
determined after 6 d with crystal violet. Similar results were obtained in two additional experiments. Asterisks denote significant differences (P   0.05, t test).
(inset) PC-3 cells stably transfected with V5-AGK were incubated for 6 d without (None) or with AG1478, and AGK expression was determined by immu-
noblotting with anti-V5 antibody. The blot was stripped and reprobed with anti-tubulin as a loading control. 
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AGK promotes transactivation of EGFR
 
Many studies have led to the notion that LPA is important in
the pathophysiology of prostate carcinoma functioning in an
emerging paradigm of cross talk between LPA receptors and
the tyrosine kinase EGFR (Prenzel et al., 1999; Mills and
Moolenaar, 2003). Therefore, it was of importance to deter-
mine whether overexpression of AGK and increased LPA
levels resulted in such receptor transactivation leading to en-
hanced growth.
In serum-starved cells, AGK expression increased tyro-
sine phosphorylation of several proteins, notably a 170-kD
band, which was similarly increased by serum in vector trans-
fectants (Fig. 5 B). Kinetic analysis revealed that the 170-kD
tyrosine phosphorylation induced by serum was a rapid event
in AGK-expressing cells, clearly evident within 5 min and re-
maining elevated for at least 60 min (Fig. S4 A, available at
http://www.jcb.org/cgi/content/full/jcb.200407123/DC1). The
enhanced tyrosine phosphorylation of the 170-kD protein rep-
resented activation of the EGFR, as immunoblotting of anti-
EGFR immunoprecipitates with anti-phosphotyrosine revealed
increased EGFR tyrosine phosphorylation in cells overexpress-
ing AGK, even in the absence of serum (Fig. 5 C).
 
AGK-induced extracellular signal related 
kinase (ERK) 1/2 activation 
requires EGFR
 
Previously, it has been suggested that EGFR activation is re-
quired for signal relay from LPA receptors to ERK1/2 activa-
tion in prostate cancer cells (Prenzel et al., 1999; Kue et al.,
2002; Raj et al., 2002). AGK expression markedly increased
activation of ERK1/2, as determined with a phospho-specific
antibody, which was further enhanced by serum (Fig. 5 B) and
EGF (Fig. 5 D and Fig. S3 C). To further confirm that activa-
tion of the EGFR was necessary for AGK-stimulated ERK acti-
vation, we used the specific EGFR tyrosine kinase inhibitor,
tyrphostin AG1478. As expected, AG1478 abolished EGFR-
induced tyrosine phosphorylation (Fig. S4 B). AG1478
blocked AGK-mediated ERK1/2 phosphorylation (Fig. 5 D)
and decreased its mitogenic effect (Fig. 5 E) and also inhibited
MOG-stimulated proliferation by 35 
 
 
 
 4%. Nonetheless, pro-
longed treatment with AG1478 did not affect AGK protein
levels (Fig. 5 E, inset).
 
Involvement of AGK in motility
 
Transactivation of the EGFR has also been implicated in motil-
ity of cancer cells (Gschwind et al., 2001). In agreement, AGK
overexpression enhanced migration of PC-3 cells toward EGF,
which was blocked by the EGFR inhibitor AG1478 (Fig. 6 A).
AGK also enhanced migration of NIH 3T3 fibroblasts toward
serum (Fig. S3 B).
In the Boyden chamber cell migration assay, differences
in cell shape and size may affect passage through the pores in
the membrane but do not affect the in vitro wound closure as-
say. AGK expression also enhanced closure of the wounded
area, especially in the presence of EGF and the AGK sub-
strate MOG (Fig. 6, B and C). In contrast, wound closure in-
duced by LPA was not affected by AGK expression. AGK-
induced wound closure was also blocked by AG1478, sup-
porting a role for EGFR transactivation in AGK-induced mi-
gratory responses.
 
AGK up-regulates IL-8
 
Expression of the multifunctional cytokine IL-8 correlates
with angiogenesis, tumorigenicity, and metastasis of human
prostate cancer cells implanted in nude mice (Kim et al.,
2001). Similarly, LPA markedly enhanced IL-8 secretion
from PC-3 cells. Expression of AGK slightly increased IL-8
release, which was further significantly increased by addi-
tion of MOG, the precursor of LPA (Fig. 6 D). The EGFR in-
hibitor AG1478 only slightly decreased LPA-induced IL-8
secretion, suggesting that this response is independent of
EGFR transactivation.
 
Involvement of endogenous AGK in 
ERK1/2 activation and cell cycle 
progression
 
Serum and EGF induced significant increases in AGK expres-
sion as determined by quantitative real-time PCR (Fig. 7 A).
It has previously been shown that LPA itself is sufficient to
increase its own production in PC-3 cells, indicating the pres-
Figure 6. EGFR is required for AGK-stimulated cell migration toward EGF
and wound closure. (A) PC-3 cells transfected with vector (open bars) or
AGK (closed bars) were pretreated without or with 200 nM AG1478 for
20 min and allowed to migrate for 3 h toward EGF (10 ng/ml). The data
are means   SD of two determinations. Similar results were obtained in
two independent experiments. (B and C) Monolayers of vector (open bars)
or AGK (closed bars) PC-3 transfectants were wounded and treated with
vehicle, MOG (10  M), LPA (10  M), or EGF (10 ng/ml). Where indi-
cated, cells were also treated with 200 nM AG1478. (B) Representative
images of a wound healing assay with vector and AGK-transfected PC-3
cells before and 24 h after treatment with MOG. (C) Migration of cells
into the wound was determined after 24 h by processing digital photo-
graphs with ImagePro Plus. (D) AGK induces IL-8 secretion. PC-3 cells
transfected with vector (open bars) or AGK (closed bars) were serum
starved for 24 h and treated in serum-free DME with or without MOG
(10  M) or LPA (1  M) for 16 h, and IL-8 secretion was measured by
ELISA. Where indicated, cells were also treated with 200 nM AG1478.
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ence of an autocrine network (Qi et al., 1998). Consistent with
an autocrine function for LPA, we found that LPA also in-
creased expression of AGK by threefold in naïve PC-3 cells
(Fig. 7 A). To examine the physiological function of AGK, its
expression was down-regulated with small interfering RNA
(siRNA). siAGK, but not control siRNA, markedly reduced
AGK mRNA in PC-3 cells, as determined by QPCR, without
influencing expression of SphK1 (Fig. 7 B). Consistent with
its role in synthesis of LPA and PA, the most striking effect of
down-regulating AGK was reduction of mitochondrial PA and
LPA by  30% (Fig. 7 C). Remarkably, siAGK completely
blocked stimulation of ERK1/2 induced by EGF (Fig. 7 D). To
rule out off-target effects, we used two additional unrelated
siRNAs targeted to different sequences of AGK. siAGK2 and
siAGK3 markedly and specifically reduced expression of AGK
determined by QPCR (0.2 and 0.16 relative to siControl) with-
out reducing expression of SphK1 (1.1 and 1.0 relative to
siControl) or SphK2 (1.1 and 1.0 relative to siControl). Impor-
tantly, both of these siRNAs also markedly reduced EGF-
induced ERK1/2 activation but did not decrease LPA-induced
ERK activation (Fig. 7 E), suggesting that LPA can bypass the
effects of down-regulation of AGK. In addition, down-regula-
tion of AGK reduced EGF-stimulated tyrosine phosphoryla-
tion of the EGFR (Fig. S3 C).
Down-regulation of AGK reduced EGF-induced wound
closure but had no effect on wound closure induced by LPA
(Fig. 7 F). siAGK also reduced migration toward EGF but not
toward serum (Fig. 7 G). siAGK but not siControl inhibited
basal secretion of IL-8 in untreated PC-3 cells and also blocked
the small effect of MOG (1.28- and 1-fold stimulation in si-
Control and siAGK, respectively; Fig. 7 H). However, its ef-
fects on EGF or LPA-induced IL-8 secretion were smaller (fold
stimulation with EGF is 2.16 and 2.06 and with LPA is 5 and
7.5 in siControl and siAGK, respectively). Similarly, siAGK2
also reduced basal IL-8 secretion without affecting LPA-
induced secretion (Fig. 7 H).
Next, we examined the role of endogenous AGK in cell
growth regulation. The levels of LPA in serum range from 1
to 6  M (Baker et al., 2001), and in 10% serum, the level is
well below the concentration needed for its mitogenic effects.
In agreement with others (Qi et al., 1998), we have found that
serum is a more potent mitogen for PC-3 cells than 10  M
LPA (unpublished data). Remarkably, siAGK markedly de-
creased DNA synthesis as measured by incorporation of
BrdU into nascent DNA, whereas nonspecific siRNA had no
effect (Fig. 8, A and B). In agreement, cell cycle analysis re-
vealed that after one day in serum-free medium,  75% of
PC-3 cells transfected with nonspecific siRNA were in Go/G1
phase and only a small fraction were in S and G2/M phases,
which was similar to untreated cells (Fig. 8 C and not de-
picted). Transfection with siAGK increased the fraction of
cells in Go/G1 and decreased the proportion in the S phase and
the G2/M phase. In the presence of 10% serum, which mark-
edly increased the proportion of cells in the S phase and G2/M
phase, siAGK, but not control siRNA, further reduced cells in
S phase, albeit to a lesser extent than in the absence of serum
(Fig. 8 C).
Figure 7. Effectiveness and specificity of siAGK. (A) Expression of endog-
enous AGK. Naïve PC-3 cells were serum starved for 24 h and treated in
DME with or without 10% serum, LPA (10  M), or EGF (100 ng/ml) for
16 h, and AGK mRNA was determined by quantitative real-time PCR.
Data were normalized to expression of 18S RNA and are means   SD of
triplicate determinations. *, P   0.05 by t test. (B) PC-3 cells were trans-
fected with control siRNA (open bars) or siRNA specific for AGK (hatched
bars) and mRNA levels of AGK and SphK1, and 18S RNA was deter-
mined by QPCR. (C) Duplicate cultures were labeled with 
32Pi for 12 h.
Phospholipids were extracted from mitochondria isolated by differential
centrifugation. Equal amounts of 
32P-phospholipids were separated by
TLC, and the indicated phospholipids were quantified with a phosphoim-
ager. The data are expressed as a percentage of total 
32P-labeled phos-
pholipids and are means   SD of duplicate determinations. *, P   0.05
by t test. (D) Down-regulation of AGK with siRNA blocks EGF-induced
ERK1/2. PC-3 cells were transfected with control siRNA or siRNA specific
for AGK and treated without (None) or with 10 ng/ml EGF for the indi-
cated times. Equal amounts of lysate proteins were separated by SDS-
PAGE, and ERK1/2 activation was determined by immunoblotting with
anti-pERK1/2. Blots were stripped and reprobed with anti-ERK2 as a load-
ing control. (E) PC-3 cells were transfected with siControl2, siAGK2, or
siAGK3 (Dharmacon), as described in Materials and methods, and treated
with EGF (10 ng/ml) or LPA (10  M) for the indicated times. Equal
amounts of lysate proteins were separated by SDS-PAGE and ERK1/2
activation determined by immunoblotting with anti-pERK1/2. Blots were
stripped and reprobed with anti-tubulin as a loading control. Down-regula-
tion of AGK decreases EGF-induced wound closure and migration. (F)
Monolayers of PC-3 cells transfected with control siRNA (open bars) or
siRNA specific for AGK (hatched bars) were wounded and treated with
vehicle (None), EGF (10 ng/ml), or LPA (10  M), and migration of cells
into the wound was determined after 24 h. (G) Cells from duplicate cul-
tures were allowed to migrate for 3 h in Boyden chambers toward vehicle
(None), EGF (10 ng/ml), or serum (10%). The data are means   SD of
two determinations. (H) Down-regulation of AGK with siRNA decreases IL-8
secretion. PC-3 cells were transfected with the indicated control siRNAs
(open bars and gray bars) or siRNAs specific for AGK (hatched bars and
black bars), incubated in serum-free DME without (None) or with MOG
(10  M), LPA (1  M), or EGF (10 ng/ml) for 16 h, and IL-8 secretion was
measured. *, P   0.05 by t test.JCB • VOLUME 169 • NUMBER 5 • 2005 808
Discussion
Several lines of evidence suggest that AGK is a bona fide
acylglycerol kinase. First, recombinant AGK catalyzes the
phosphorylation of both MOG and DAG in vitro, producing
LPA and PA, respectively. In agreement, bacterially expressed,
purified recombinant AGK phosphorylated DAG as well as
MOG (Waggoner et al., 2004). Second, overexpression of
AGK increases cellular levels of LPA and PA. Third, and con-
versely, down-regulation of AGK reduces their intracellular
levels. Fourth, overexpression of kinase dead AGK, although
localized similarly to the mitochondria as wild-type AGK, does
not increase acylglycerol kinase activity nor produce LPA.
Prostate carcinomas often possess an autocrine stimula-
tory loop in which the transformed cells express high levels of
EGFR and also produce activating ligands. One such ligand
might be the bioactive phospholipid LPA, which stimulates
prostate cancer cell proliferation, migration, and survival, not
only by acting on its cognate GPCRs but also by stimulating
metalloproteinase activity and proteolytic EGF precursor pro-
cessing leading to EGFR transactivation (Gschwind et al.,
2001). Our identification of AGK as a lipid kinase that pro-
duces LPA and PA and is highly expressed in prostate tumors
may have important clinical implications with regard to ad-
vanced prostate cancer. AGK not only regulates mitogenic
EGFR signaling that plays important roles in androgen-refrac-
tory metastatic prostate cancer but also stimulates cell motility
and EGFR-independent secretion of the pluripotent cytokine
IL-8. Indeed, blockade of the EGFR in PC-3 cells inhibited tu-
mor growth and invasion and also down-regulated expression
of IL-8 within the tumors (Karashima et al., 2002).
Interestingly, the endocannabinoids anandamide and 2-AG
potently inhibit proliferation and cause apoptosis of PC-3 and
DU145 prostate cancer cells (Melck et al., 2000). Because
AGK can phosphorylate 2-AG converting it to LPA, it may
regulate the dynamic levels of these counterregulatory lipids
that have been shown to play opposing roles in growth and sur-
vival of prostate cancers. Of note, LPA3 was originally cloned
from prostate cancer cells (Im et al., 2000), which is concor-
dant with the ability of LPA to induce autocrine proliferation of
these cells (Xie et al., 2002). Moreover, PC-3 cells express
LPA1-3 receptors, thus providing AGK with the potential to ac-
tivate numerous downstream growth signaling pathways.
The mitogenic responses of some mammalian cells to
LPA may be LPA1-4 independent (Hooks et al., 2001). How-
ever, in prostate cancer cells, LPA transduces mitogenic sig-
nals via activation of G i and G   subunits (Kue and Daaka,
2000; Bookout et al., 2003). Importantly, the expression of
GRK2ct inhibited PC-3 tumor formation in animals (Bookout
et al., 2003). Several lines of evidence indicate that the growth-
promoting effects of AGK are mediated via LPA receptors. In
RH7777 cells, which are devoid of LPA1-4, expression of AGK
had no effect on DNA synthesis, even in the presence of ex-
ogenous MOG. Moreover, PTX pretreatment decreased the
growth-promoting effects of AGK. Our results are similar to
others showing that PTX not only inhibits proliferation of PC-3
cells induced by LPA but also inhibits the effect of serum more
drastically (Kue and Daaka, 2000). Furthermore, consistent
with a previous study (Lea et al., 2004), GW9662, a selective
antagonist of PPAR , inhibited proliferation of vector-trans-
fected PC-3 cells, and yet it did not abrogate the mitogenic ef-
fect of AGK. Our results are consistent with the notion that
production and secretion of LPA by AGK induces Gi-depen-
dent proliferation, likely through LPA receptors. Remarkably,
down-regulation of AGK drastically reduced ERK1/2 activa-
tion induced by EGF, which, as expected, was bypassed by ad-
dition of the AGK product, LPA. Our data suggest that AGK
plays an important role in EGF-induced mitogenic ERK signal-
ing. AGK also phosphorylates DAG to produce the bioactive
mediator PA, which regulates numerous biological processes
including Raf translocation to the plasma membrane (Rizzo et
al., 1999) and activation of mTOR (Fang et al., 2001). Our re-
sults also imply that specific pools of PA may play important
roles in growth signaling.
Figure 8. Involvement of endogenous AGK in cell proliferation.
(A) PC-3 cells were transfected with control siRNA (open
bars) or siAGK (hatched bars) and serum starved for 8 h.
After culturing for an additional 16 h in serum-free medium
or in medium supplemented with 10% serum, BrdU was
added for 3 h and the fraction of cells incorporating BrdU
was determined. Data are means   SD of duplicate cultures
from a representative experiment. At least three different
fields were scored with a minimum of 100 cells per field.
Similar results were obtained in two independent experi-
ments. (B) Representative fluorescent and phase images of si-
Control and siAGK-transfected cells. (C) Cell cycle analysis.
PC-3 cells transfected with control siRNA or siAGK were cul-
tured in serum-free medium or in medium supplemented with
10% serum. After 24 h, cellular DNA was stained with pro-
pidium iodide and cell cycle analysis was performed with an
Epics XL-MCL flow cytofluorometer (Beckman Coulter). Aster-
isks indicate significant differences from vector-transfected
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Although the physiological function of LPA and PA gen-
eration in the mitochondria is not clear, a LPA phosphatase
with 28.5% amino acid identity to human prostatic acid phos-
phatase is also localized to the mitochondria (Hiroyama and
Takenawa, 1999). This LPA phosphatase has been suggested to
regulate lipid metabolism in mitochondria by hydrolysis of
LPA to monoacylglycerol (Hiroyama and Takenawa, 1999).
Previous studies suggest that mitochondria-produced LPA can
leave this organelle and be transported to the ER in the pres-
ence of liver fatty acid binding protein, can be secreted, and/or
can be converted to PA (Haldar and Lipfert, 1990; Chakraborty
et al., 1999; Hiroyama and Takenawa, 1999). In addition, LPA
generated by prostate cancer cells in response to mitogenic
stimuli can be secreted (Qi et al., 1998; Gibbs et al., 2000; Kue
and Daaka, 2000; Kue et al., 2002; Xie et al., 2002).
It has been demonstrated that in both PC-3 and DU145
prostate cancer cells, agonists induce 18:1 LPA formation that
is then released into the medium (Xie et al., 2002). As Du145
and PC-3 cells express LPA1-3, it was suggested that 18:1 LPA
can act as an autocrine mediator (Xie et al., 2002), yet the criti-
cal enzymes involved have not been identified. Our data sug-
gest that AGK could be a missing link. Production of LPA by
AGK, which in turn transactivates the EGFR, can amplify mi-
togenic and survival signals. Moreover, expression of AGK is
stimulated by EGF, serum, and even by LPA itself, thereby
providing a positive feed-forward stimulus that could further
enhance EGFR-dependent and -independent processes impor-
tant for cancer progression. Therefore, targeting AGK, which is
upstream of the EGFR, could offer additional therapeutic bene-
fits in treatment of androgen-independent prostate cancer.
Materials and methods
Cloning of an AGK
An EST (AW321722) was identified that contained an open reading
frame with 25% identity and 50% similarity to hSphK2 from aa 133 to
256. 5  and 3  RACE were performed using the GeneRacer kit (Life Tech-
nologies) to obtain the sequence of the full-length open reading frame. A
cDNA with a complete open reading frame was cloned from a human kid-
ney cDNA library encoding a 422–amino acid polypeptide with a calcu-
lated molecular mass of 46,400 D (Fig. S1). A nearly identical mouse ho-
mologue (CAC06108) was also identified.
The predicted sequence of this human protein and its mouse homo-
logue identified from the mouse database (CAC06108) are 95% identical
and both show sequence similarity to SphKs, especially in the five con-
served SphK domains (Liu et al., 2000, 2002). We previously noted that
conserved regions 1–3 of SphKs have high sequence homology with the
catalytic domain of DAGKs (DAGKc; Liu et al., 2002). This region (aa 65
to 191 of the new kinase) contains the GDGXXXEXXXGXXXRXnK (n   7, 8)
motif, present in the catalytic domain of SphKs (SphKc; Liu et al., 2002),
which is reminiscent but distinct from the sequence GGDGXXG previously
suggested to be part of the ATP binding site of DAGKc (Topham and Pres-
cott, 1999). Of note, a lysine residue downstream of the glycine-rich re-
gion, which is conserved in the ATP binding sites of protein kinases (Hanks
et al., 1988) and absent in DAGKc, is also present in SphKc and in this
new lipid kinase (Fig. S1). However, Clustal W alignment revealed that
hSphK1 and hSphK2 are more closely related to each other than to this
new putative lipid kinase. Pairwise comparisons of the conserved subdo-
mains of SphK1/SphK2, new lipid kinase/SphK1, new lipid kinase/
SphK2, new lipid kinase/CERK, and new lipid kinase/DAGK indicated se-
quence identities of 53, 29, 23, 26, and 24%, respectively. These compar-
isons suggest that this new lipid kinase may be unique. A search of the hu-
man genome database revealed that the gene encoding this lipid kinase is
located on chromosome 7q34, whereas SphK1 and SphK2 have been lo-
calized to chromosomes 17q25.2 and 19q13.2, respectively.
Cell culture and transfection
Human PC-3 prostate cancer cells (CRL-1435; American Type Culture Col-
lection), NIH 3T3 fibroblasts (CRL-1658; American Type Culture Collec-
tion), rat hepatoma RH7777 cells (provided by X. Fang, Virginia Com-
monwealth University, Richmond, VA), and human embryonic kidney cells
(HEK 293; CRL-1573; American Type Culture Collection) were seeded at
4–5    10
5 cells per well in 6-well plates and transfected with Lipo-
fectamine PLUS for NIH 3T3, HEK 293, and RH7777 cells and Lipo-
fectamine 2000 for PC-3 cells, according to the manufacturer’s instruc-
tions (Life Technologies).
Catalytically inactive AGK
The QuikChange site-directed mutagenesis kit (Stratagene) was used to
prepare catalytically inactive AGK (G126E) by mutating the conserved
glycine in the glycine-rich loop of the ATP binding site (forward primer,
5 -TTGGAGGAGGAGATGAGACACTGCAGGAGGTT-3 , and reverse
primer, 5 -AACCTCCTGCAGTGTCTCATCTCCTCCTGCAA-3 ). The muta-
tion was confirmed by sequencing.
siRNA transfection
AGK expression was down-regulated with sequence-specific siRNA.
siRNA target sequence for AGK (siAGK: 5 -AACAGATGAGGCTACCT-
TCAG-3 ) and control siRNA (5 -TTCTCCGAACGTGTCACGT-3 ) were
obtained from QIAGEN. In some experiments, cells were transfected with
two additional AGK siRNAs (siAGK2: 5 -GAGGCTACCTTCAGTAAGA-3 ;
siAGK3: 5 -GGAGAGACCAGTAGTTTGA-3 ) and siControl (non-targeting
siRNA with at least four mismatches to all human and mouse genes from
Dharmacon). Cells (3   10
5) were transfected in 6-well dishes for 3–4 h
with the RNA duplexes (200 nM) using Oligofectamine (Life Technologies)
according to the manufacturer’s protocol. 90   2% of the cells were trans-
fected as determined with siGLO RISC-Free siRNA (Dharmacon).
Real-time PCR
Quantitative real-time PCR was performed on a real-time PCR machine
(model Taqman ABI 7900; Applied Biosystems) with the following prim-
ers/probes: AGK forward primer, 5 -CGAAGGCTTGCGTCCTACTG-3 ;
reverse primer, 5 -TGGTGGACAGCTGCACATCT-3 ; probe, 5 -CACA-
ACCACAGGATGCCCTTTCCC-3  (Integrated DNA Technologies); pre-
mixed primer-probe set for hSphK1 was purchased from Applied Biosys-
tems. Ribosomal RNA (18S rRNA) measured using TaqMan assay
reagents served as endogenous control.
Lipid kinase activity
Lipids (100 nmol) were dried under N2 and resuspended in 180  l of
buffer containing 100 mM MOPS, pH 7.2, 2 mM EGTA, 15 mM NaF, 2
mM orthovanadate, 50 mM NaCl, 250 mM sucrose, 0.03% deoxycho-
late, and 1:500 diluted protease inhibitor cocktail (Sigma-Aldrich). After
brief sonication, 10  l lysates (10  g) and 10  l  -[
32P]ATP (10  Ci, 1 mM)
containing MgCl2 (10 mM) were added and reactions were performed
for 30 min at 37 C. 
32P-labeled lipids produced were extracted into 0.8 ml
CHCl3/MeOH/concentrated HCl (100:200:1, vol/vol), and phase sepa-
ration was effected by adding 0.25 ml 2 M KCl and 0.25 ml CHCl3. Al-
iquots of the organic phases were analyzed by TLC on silica gel G60
with CHCl3/acetone/methanol/acetic acid/water (10:4:3:2:1, vol/vol)
as solvent and the radioactive spots corresponding to migration of stan-
dards were quantified with an FX Molecular Imager (Bio-Rad Laborato-
ries). In some experiments, SphK1 (Liu et al., 2000), SphK2 (Liu et al.,
2000), ceramide, and DAGKs (Sugiura et al., 2002) were measured
exactly as described.
AGK activity in immunoprecipitates
HEK 293 cells were seeded in 10-cm dishes and transiently transfected
with vector or V5-tagged AGK. 24 h later, cells were lysed by sonication
in buffer containing 100 mM MOPS, pH 7.2, 2 mM EGTA, 2 mM ortho-
vanadate, 2 mM  -glycerophosphate, 150 mM NaCl, 250 mM sucrose,
and 1:500 diluted protease inhibitor cocktail. Lysates were cleared by
centrifugation and 400  g of protein in 250  l was incubated with 1  g
anti-V5 (Invitrogen) for 4 h at 4 C. Protein A/G PLUS–Agarose beads
(10  l; Santa Cruz Biotechnology, Inc.) were added and incubated for an
additional 1 h. The beads were washed four times with the same buffer,
resuspended in 10  l, and AKG activity was determined.
32P labeling of cellular phospholipids
Vector and kinase PC-3 transfectants were grown to 80–90% confluency
in 100-mm dishes, incubated for 2 h with 40  Ci/ml 
32Pi in phosphate-
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phosphate-free DME. Medium was removed and after brief centrifugation
lipids were extracted from a 3-ml aliquot of the medium by addition of
10.8 ml chloroform/methanol/concentrated HCl (100:200:1, vol/vol),
followed by 3.6 ml each of chloroform and 2 M KCl. Lipids were also ex-
tracted from the cells after washing and scraping into 1.2 ml cold metha-
nol/concentrated HCl (100:1), followed by addition of 0.6 ml chloroform.
After vigorous vortexing, 0.6 ml CHCl3 and 0.5 ml H2O was added.
Phases were separated by addition of 0.6 ml 2 M KCl. The organic
phases were transferred to siliconized glass tubes and the aqueous phases
reextracted with 0.6 ml CHCl3. Aliquots containing 50,000 cpm were
separated by two-dimensional TLC (Yokoyama et al., 2000). Radioactive
spots were identified by comparison to standard phospholipids and quan-
tified with a phosphoimager. In some experiments, phospholipids were
separated by one-dimensional TLC using CHCl3/methanol/water/ammo-
nium hydroxide (120:75:6:2, vol/vol; Liu et al., 2003).
Northern analysis and matched tumor/normal expression array
Poly(A)
  RNA blot of multiple adult human tissues (CLONTECH Laborato-
ries, Inc.) was used for Northern blotting analysis of AGK expression. The
blot was hybridized with a probe prepared by labeling the PCR product
with  -[
32P]dCTP in ExpressHyb buffer (CLONTECH Laboratories, Inc.) at
65 C overnight. A matched tumor/normal expression array (CLONTECH
Laboratories, Inc.) was similarly probed with radiolabeled full-length AGK.
Chemotactic motility
Chemotaxis was measured in a modified Boyden chamber using collagen-
coated polycarbonate filters (25   80 mm, 8- M pore size) as previously
described (Wang et al., 1999).
In vitro wound closure assay
Confluent monolayers of PC-3 cells were serum starved for 24 h,
wounded by making a uniform scratch with a pipet tip, and washed to re-
move detached cells. Wound closure was monitored after 24 h in serum-
free medium by determining the number of cells migrating into the wound
using ImagePro Plus software to analyze digital images from an inverted
phase microscope.
Cell proliferation assays
PC-3 cell proliferation was determined with crystal violet (Olivera et al.,
1999). In some experiments, cell growth was measured by adding WST-1
reagent (Roche) and incubating at 37 C for 3 h. Absorbance was mea-
sured at 450 nm with background subtraction at 650 nm. BrdU incorpora-
tion and analysis of cell cycle profile by flow cytometry were performed
exactly as described previously (Olivera et al., 1999).
IL-8 secretion
PC-3 cells were serum starved overnight, and after stimulation in serum-
free DME for 16 h, media was collected and briefly centrifuged to re-
move cells. Secreted IL-8 was determined with the Quantikine IL-8 ELISA
kit (R&D Systems).
Immunofluorescence and confocal microscopy
Cells were grown on glass coverslips and transfected with vector or V5-
tagged AGK. 24 h later, cells were incubated with 200 nM MitoTracker
red CMXRos (Molecular Probes) to stain mitochondria and fixed in 3%
PFA in PBS containing 0.1% Triton X-100. ER was visualized with poly-
clonal rabbit anti-calnexin antibody followed by anti–rabbit IgG-FITC.
Transfected cells were visualized simultaneously with anti-V5 antibody
(1:500; Invitrogen) followed by a secondary anti–mouse antibody conju-
gated with FITC or Texas red (Molecular Probes), respectively. Coverslips
were mounted on glass slides using an Anti-Fade kit (Molecular Probes)
and examined by confocal microscopy. Images were collected with a
laser scanning microscope (model IX70; Olympus) equipped with argon
(488 nm) and krypton (568 and 647 nm) lasers and a 60 /1.4 NA
PlanApo lens. Quantitative image analysis was performed using Meta-
morph image processing software.
Subcellular fractionation
Cells transfected with vector or AGK were Dounce homogenized in buffer
containing 20 mM Hepes, pH 7.4, 10 mM KCl, 2 mM MgCl2, 1 mM
EDTA, 250 mM sucrose, 10  g/ml aprotinin, 10  g/ml leupeptin, and 1
mM PMSF. Subcellular fractionation was performed by differential centri-
fugation at 4 C as described previously (Le Stunff et al., 2002). In brief, ly-
sates were centrifuged at 1000 g for 5 min to remove unbroken cells and
nuclei (P1, nuclei and unbroken cells); postnuclear supernatants were cen-
trifuged at 5,000 g for 10 min (P2, mitochondria); followed by 17,000 g
for 15 min (P3, intracellular membrane fraction containing ER and Golgi).
The remaining supernatant was centrifuged at 100,000 g for 1 h to ob-
tain plasma membranes. Proteins were separated by SDS-PAGE, trans-
ferred to nitrocellulose membranes, and probed with antibodies as de-
scribed in the figure legends.
Immunoprecipitation
PC-3 cells were lysed in buffer containing 25 mM Hepes, pH 7.5, 0.3 M
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, 20 mM  -glycerophosphate, 1 mM sodium
orthovanadate, 0.5 mM dithiothreitol, 1 mM PMSF, and 10  g/ml leu-
peptin. Lysates were cleared by centrifugation at 10,000 g for 10 min
and incubated with 2  g anti-EGFR antibody for 2 h at 4 C. 20  l of pro-
tein A/G–Sepharose beads (Santa Cruz Biotechnology, Inc.) were added
and incubated for an additional 1 h at 4 C. Sepharose beads were
washed and boiled in SDS sample buffer, and bound proteins were ana-
lyzed by Western blotting.
Online supplemental material
Fig. S1 shows a Clustal W alignment of AGK with other lipid kinases. Fig.
S2 demonstrates the mitochondrial localization of AGK and catalytically
inactive AGK and confirms that the mutant has no kinase activity. Fig. S3
shows the effect of AGK on growth and survival of NIH 3T3 cells. Fig. S4
shows regulation of EGFR phosphorylation by AGK. Online supplemental
material is available at http://www.jcb.org/cgi/content/full/jcb.
200407123/DC1.
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